Computational Characterization of Convolvamine: Cholinesterase and Receptor Screening with ADMET Profiling
Year: 2026
Type: preprint
Abstract: Acetylcholinesterase (AChE) inhibition is an established strategy for the symptomatic treatment of Alzheimer’s disease. Convolvamine is a tropane alkaloid from Convolvulus pluricaulis, a plant traditionally used for neurological indications. However, the potential of isolated convolvamine as a cholinesterase inhibitor remains poorly characterized. We compared convolvamine with donepezil, galantamine and rivastigmine using docking, ADMET prediction, triplicate 200 ns AChE and butyrylcholinesterase (BChE) simulations, and a screen against six proteins with AChE-like binding sites. Convolvamine remained in the AChE gorge while contacting the catalytic-site residues Trp86 and Tyr337 and the peripheral residues Tyr124 and Tyr341. The mean molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) ΔTOTAL of convolvamine was closest to galantamine. No AChE-over-BChE difference was resolved within the sampled simulations. We performed simulations for likely off-targets and identified the α2C adrenergic and glucocorticoid receptors as potential off-target liabilities that should be considered. ADMET models predicted high gastrointestinal absorption and blood-brain-barrier permeation alongside hERG and CYP2D6 liabilities and further alerts consistent with the approved comparators. These calculations support experimental evaluation of convolvamine activity against AChE and BChE and identify potential liabilities for further study.
Source: Preprints.org
Authors: Shreyas Gowrishetty, Yash Bhargava
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: acetylcholinesterase inhibition, butyrylcholinesterase, Alzheimer's disease, tropane alkaloids, Convolvulus pluricaulis, molecular docking, MM-PBSA binding free energy, off-target binding, alpha2C-adrenergic receptor, glucocorticoid receptor, ADMET prediction, blood-brain barrier permeability, hERG liability, donepezil, galantamine, rivastigmine
Open Access status: green
OpenAlex ID: W7234204384
